Clinical Trial Update: Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating benralizumab for moderate to severe atopic dermatitis was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Benralizumab (benralizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Atopic Dermatitis | Phase 2 | Status: TERMINATED | Results posted: 2023-06-27